Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.

International journal of clinical oncology - 1 Oct 2024

Matsubara Nobuaki, Miura Yuji, Nishiyama Hiroyuki, Taoka Rikiya, Kojima Takahiro, Shimizu Nobuaki, Hwang Jason, Ote Tatsuya, Oyama Ryo, Toyoizumi Kiichiro, Mukhopadhyay Sutapa, Triantos Spyros, Deprince Kris, Loriot Yohann

Abstract excerpt

BACKGROUND: In the THOR trial (NCT03390504) Cohort 1, erdafitinib demonstrated significantly prolonged overall survival (OS) (median 12.1 versus 7.8 months) and reduced risk of death by 36% (hazard ratio 0.64, P = 0.005) compared with chemotherapy in metastatic urothelial carcinoma (mUC) patients with FGFR alterations who progressed after ≥ 1 prior treatments, including anti-PD-(L)1. There have been no reports of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to East Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Progression-Free Survival

Share to Pyrazoles

Share to Quinoxalines

Share to Receptors, Fibroblast Growth Factor

Share to Urinary Bladder Neoplasms

Share to Urologic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 39017806
DOI: 10.1007/s10147-024-02583-3
PMCID: PMC11420312

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.PMID 39017806Read ↗

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Semantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.Semantic proximity Read ↗

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.Semantic proximity Read ↗

Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.Semantic proximity Read ↗

Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.Semantic proximity Read ↗

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Semantic proximity Read ↗

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.Semantic proximity Read ↗

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.Semantic proximity Read ↗

Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.